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Abstract
Purpose: Over the past 20 years, neuroinflammation (NI) has increasingly been recognised as having an
important role in many neurodegenerative diseases, including Alzheimer’s disease. As such, being able
to image NI non-invasively in patients is critical to monitor pathological processes and potential therapies
targeting neuroinflammation. The translocator protein (TSPO) has proven a reliable NI biomarker for
positron emission tomography (PET) imaging. However, if TSPO imaging in acute conditions such as
stroke provides strong and reliable signals, TSPO imaging in neurodegenerative diseases has proven
more challenging. Here, we report results comparing the recently developed TSPO tracers [18F]GE-180
and [18F]DPA-714 with (R)-[11C]PK11195 in a rodent model of subtle focal inflammation.
Procedures: AdultmaleWistar ratswere stereotactically injectedwith 1μg lipopolysaccharide in the right
striatum. Three days later, animals underwent a 60-min PET scan with (R)-[11C]PK11195 and [18F]GE-
180 (n = 6) or [18F]DPA-714 (n = 6). Ten animals were scanned with either [18F]GE-180 (n = 5) or
[18F]DPA-714 (n = 5) only. Kinetic analysis of PET data was performed using the simplified reference
tissuemodel (SRTM)with a contralateral reference region or a novel data-driven input to estimate binding
potential BPND. Autoradiography and immunohistochemistry were performed to confirm in vivo results.
Results: At 40–60 min post-injection, [18F]GE-180 dual-scanned animals showed a significantly
increased core/contralateral uptake ratio vs. the same animals scanned with (R)-[11C]PK11195
(3.41 ± 1.09 vs. 2.43 ± 0.39, p = 0.03); [18]DPA-714 did not (2.80 ± 0.69 vs. 2.26 ± 0.41). Kinetic
modelling with a contralateral reference region identified significantly higher binding potential (BPND) in
the core of the LPS injection site with [18F]GE-180 but not with [18F]DPA-714 vs. (R)-[11C]PK11195. A
cerebellar reference region and novel data-driven input to the SRTM were unable to distinguish
differences in tracer BPND.
Conclusions: Second-generation TSPO-PET tracers are able to accurately detect mild-level NI. In this
model, [18F]GE-180 shows a higher core/contralateral ratio and BPND when compared to (R)-
[11C]PK11195, while [18F]DPA-714 did not.
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Introduction
Inflammation is known to play a role in the development and
progression of a wide variety of neuropathological condi-
tions, including stroke [1], multiple sclerosis [2] and
neurodegenerative diseases [3, 4]. Sensitive and spatially
accurate imaging of neuroinflammation (NI) in vivo, how-
ever, has long been a challenge. Microglia, which are
resident immune cells of the brain, are in a state of
ramification and constantly probing against potential insult
or injury, even in the healthy brain [5–7]. Once activated,
they begin to alter their morphology, becoming increasingly
macrophage-like and releasing pro-inflammatory cytokines
such as interleukin-1 (IL-1) and tumour necrosis factor-α
(TNF-α). Whether this cytokine cascade exacerbates damage
or helps to restore equilibrium conditions varies depending
on the nature of the insult and with time [8]. The 18 kDa
translocator protein (TSPO), a mitochondrial protein which
is primarily located in the membranes of mitochondria [9], is
expressed at a low level in the healthy mammalian brain.
Although the true role of TSPO in NI remains to be fully
understood, an increase in expression of the protein is well
established as a correlate with the level of microglial
activation, proliferation and/or level of infiltrated macro-
phages, and to some extent astrogliosis [2, 10–12].
Positron emission tomography (PET) studies of neuroin-
flammation have been conducted for over 30 years. The
original and still most widely used radioligand for TSPO in
clinical imaging is the C-11 labelled R-enantiomer of 1-(2-
chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline
carboxamide, (R)-[11C]PK11195. Despite its application to a
wide range of diseases in the clinic, the sensitivity and
quantification of this tracer have been hampered by its high
level of non-specific binding and low free fraction in plasma
in humans, which lead to a poor signal to noise ratio [13].
Additionally, labelling of the ligand with C-11 requires an
on-site cyclotron and its radiosynthesis is well-known to be
troublesome. In recent years, therefore, efforts have been
made to develop and characterise so-called ‘second gener-
ation’ TSPO ligands with lower non-specific binding, which
have exhibited varying levels of success in clinical and
preclinical studies. Unfortunately, and unlike (R)-
[11C]PK11195, second-generation TSPO ligands are affected
by a single-nucleotide polymorphism (rs6971, Ala147Thr) in
the TSPO gene which results in variable binding affinity in
humans [14] but which has never been reported in animals.
O n e s u c h l i g a n d i s N ,N - d i e t h y l - 2 - [ 4 - ( 2 -
[18F]fluoroethoxy)phenyl]-5,7-dimethyl-pyrazolo[1,5-a]py-
rimidine-3-acetamide ([18F]DPA-714) [15], which was ini-
tially evaluated in vivo in a rodent model of acute
neuroinflammation using α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) [16] and then in models
of stroke and Herpes encephalitis [17, 18]. Compared to (R)-
[11C]PK11195, the tracer showed lower non-specific binding
and improved bioavailability in brain tissue in the AMPA
and stroke models, leading to a better signal to noise ratio
than (R)-[11C]PK11195; however, this was not the case in
the Herpes encephalitis model. Moreover, a more recent
preclinical study using [18F]DPA-714 in a longitudinal
model of HIV-1 in transgenic rats showed no significant
group differences in tracer uptake between diseased and
wild-type animals [19]. Altogether, these reports support the
idea that lower and diffuse NI as observed in neurodegen-
erative diseases is more variable and difficult to detect [16–
18]. Nevertheless, the initial evaluation in humans also
suggests that this tracer is a promising TSPO ligand [20] and
recently a large clinical study in Alzheimer’s disease (AD)
patients showed that neuroinflammation was present in both
prodromal and confirmed AD patients [21]. Another second
generation tracer, S-N,N-diethyl-9-[2-[18F]fluoroethyl]-5-
methoxy 2,3,4,9-tetrahydro-1H-carbazole-4-carboxamide
([18F]GE-180), has been used in in vitro, ex vivo and
in vivo studies on the detection of microglial activation in
acute models of NI [22, 23]. Both studies found an improved
signal to noise ratio of [18F]GE-180 over (R)-
[11C]PK11195, but both also used models that induced
strong and acute NI (i.e., high dose of lipopolysaccharide
(LPS) and stroke) and not the more challenging low/mild NI.
Another study in a transgenic AD mouse model, however,
did identify increased binding in aged wild-type and AD
animals, although this result was semi-quantitative and did
not directly compare the behaviour of [18F]GE-180 with
other tracers [24].
As mentioned above, most of the previous preclinical
studies testing second-generation TSPO tracers have primar-
ily used either acute excitotoxic lesion models or models of
stroke relevant to the strong levels of NI observed in stroke
or brain trauma. In neurodegenerative diseases and models
of neurodegeneration, however, the level of TSPO expres-
sion is much lower and more widespread than in focal
lesions [25–27] and is thus more difficult to detect and
quantify. Hence, there is a need to develop an easy-to-
perform, robust preclinical model, with low levels of TSPO
expression that are clinically relevant to those observed in
neurodegeneration. To this end, we performed a comparative
evaluation of (R)-[11C]PK11195, [18F]DPA-714 and
[18F]GE-180 in rodents injected in the striatum with a low
dose (1 μg) of LPS that induces a lower level of
neuroinflammation when compared to previously published
doses (50 μg [28]), and animals were scanned 3 days post-
injection which is after the peak of neuroinflammation
induced by LPS between 6 and 12 h post-injection [22, 28].
Kinetic analysis and modelling of preclinical PET data is
difficult; as well as being technically challenging, arterial
sampling of rodents is terminal, while reference tissue
models using the contralateral hemisphere [16, 29] as input
are hampered by the fact that the region may not be devoid
of specific binding in certain disease models. Moreover,
Folkersma et al. [30] suggest that PET data from any disease
model where blood brain barrier (BBB) damage is present
cannot be quantified using a reference tissue approach with
anatomical reference input. Many studies have resorted to
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semi-quantitation, including use of standardised uptake
values (SUVs) [31] and lesion-to-background ratios [32].
There is no consensus over tracer or model-specific
quantification approaches, but previous studies involving a
unilateral effect have used the cerebellum [33] or a
contralateral reference region [22, 23] together with the
simplified reference tissue model (SRTM) or MRTM
(multilinear reference tissue model) [34]. However, there
is, to date, no such evaluation in a model of low-level
inflammation where the target vs. the contralateral reference
region is lower and identification and quantification of the
lesion is more challenging.
Indeed, due to the presence of potentially widespread
brain inflammation, these anatomically defined reference
regions may also contain TSPO in disease. Therefore, data-
driven methods have previously been employed in clinical
(R)-[11C]PK11195 brain PET studies to extract reference
tissue kinetics in place of anatomically defined regions (see
BMethods^ section for more details and [35] for a review).
Here, we sought to adapt one such approach [36] for the
analysis of rodent PET brain scans in our model of modified
LPS injection with the three different TSPO tracers.
Thus, the overall aims of this study were to (i) assess the
performance of second-generation TSPO tracers [18F]GE-
180 and [18F]DPA-714, directly compared to (R)-
[11C]PK11195 in a modified LPS model of mild-level
neuroinflammation and (ii) test various quantification ap-
proaches in this model of NI.
Materials and Methods
Tracer Synthesis
(R)-[11C]PK11195, [18F]DPA-714 and [18F]GE-180 (Fig. 1) were
synthesised as described elsewhere [15, 23, 37–39]. Briefly, (R)-
[11C]PK11195 was formed via N-[11C]methylation of an (R)-
demethyl precursor [37, 40]; [18F]GE-180 was synthesised on a
FASTlab™ platform by nucleophilic fluorination of an S-enantio-
mer mesylate precursor [39, 41] and [18F]DPA-714 by nucleophilic
aliphatic substitution of a tosylate precursor [15].
Animals
Thirty-seven adult male Wistar rats (396 ± 52 g, Charles River,
Margate, Kent, UK) were used in this study: 22 received an LPS
injection, 2 received an AMPA injection, 5 naïve (no stereotactic
injection) rats were scanned at baseline as controls with [18F]GE-
180 (data re-analysed from that previously published [23]), 4 with
[18F]DPA-714 and 4 with (R)-[11C]PK11195. All procedures were
carried out in accordance with the Animals (Scientific Procedures)
Act 1986, and the project was approved specifically by the UK
Home Office. Animals were kept under a 12-h light-dark cycle with
free access to food and water.
LPS and AMPA Administration
For all procedures, animals were anaesthetised by isoflurane
inhalation (induction 5 % and thereafter 2–2.5 %) in O2/NO2
(30 %/70 %). Animals underwent a stereotactic injection of 1 μg
lipopolysaccharide (lipopolysaccharide from Escherichia coli
055:B5, Sigma, ref. L2880, Lot 102M4017V) or 7.5 nmol (0.5 μl
of a 15 mM solution) of AMPA (n = 2) in the right striatum via a
craniotomy (bregma +0.7 mm, lateral −3.0 mm, depth 5.5 mm from
the surface of the brain) using a 2 μl Neuros™ microsyringe
(Hamilton, USA) and micropump (injection rate 0.5 μl/min,
UltraMicroPump II® and Micro4® Controller, WPI Inc., USA).
Animals were maintained normothermic (body temperature
36.5 ± 0.5 °C, mean ± SD) during the surgery through the use of
a heating blanket (Homeothermic Blanket Control Unit, Harvard
Apparatus Limited®, Edenbridge, Kent, UK).
Scanning Protocol
Supplementary Fig. 1 presents a summary of study design; full
details of the tracer injected doses, specific activities and purities
can be found in Supplementary Table 1. Animals were split into
four groups: those scanned sequentially with (R)-[11C]PK11195
then [18F]GE-180 (group 1, n = 6) or (R)-[11C]PK11195 then
[18F]DPA-714 (group 2, n = 6) and those scanned with only
[18F]GE-180 (group 3, n = 5) or [18F]DPA-714 (group 4, n = 5). In
groups 1 and 2, animals were scanned on the same day with (R)-
[11C]PK11195 in the morning and an F-18 labelled tracer in the
Fig. 1. Chemical structures of TSPO PET radiotracers
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afternoon. Supplementary Fig. 2 shows a correlation plot between
specific activity and percentage injected dose of tracer in the
inflammatory core at 40–60 min. Although the range of specific
activities was quite broad, especially for (R)-[11C]PK11195, this
did not significantly affect brain uptake (Figs. 2, 3, 4 and
Supplementary Fig. 2).
All animals were anaesthetised by isoflurane inhalation (induc-
tion 5 % and thereafter 2–2.5 %) in O2/NO2 (30 %/70 %) at 3 days
post-LPS injection. All tracers were injected intravenously as a
bolus through a tail vein. They were then scanned on a Siemens
Inveon® small animal PET-CT as described previously [23]. The
following data acquisition protocol was used: a CT scan was
performed immediately prior to the PET scan for each animal to
acquire attenuation correction factors. The time coincidence
window was set to 3.432 ns and levels of energy discrimination
to 350 and 650 keV. List mode data from emission scans were
histogrammed into 16 dynamic frames (5 × 1 min, 5 × 2 min,
3 × 5 min and 3 × 10 min) and emission sinograms were
normalised, corrected for attenuation, scattering and radioactivity
decay and reconstructed using OSEM3D (16 subsets, 4 iterations)
into 128 × 128 × 159 images with 0.776 × 0.776 × 0.796 mm3
voxel size. Respiration and temperature were monitored throughout
the scans using a pressure-sensitive pad and rectal probe (BioVet,
M2M Imaging Corp, USA). Body temperature was maintained
through the use of a heating and fan module controlled by the rectal
probe via the interface of the BioVet system.
At the end of the PET scan, rats were rapidly decapitated and
brains removed and frozen immediately in isopentane in dry ice.
Brains were stored at −80 °C before being cut with a
cryomicrotome into adjacent 20 μm coronal slices. Sections were
then stored again at −80 °C until immunohistochemistry and
autoradiography were performed.
Fig. 2. Average core and contralateral tissue time activity curves (TACs) of LPS-injected animals that underwent dual scans






[18F]DPA-714 over 60 min duration of scans. Core/contralateral ratios indicated on the figures are calculated over the 40–
60 min time frame. Dual scan [18F]GE-180 core/contralateral ratios were significantly higher than e (R)-[11C]PK11195 (p = 0.03),
while f [18F]DPA-714 values were not (Wilcoxon signed rank, p G 0.05). Individual animals are represented by different symbols,
which correspond between (R)-[11C]PK11195 and the respective F-18 tracer. Data are presented as mean ± SD
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Image Analysis
Images were segmented automatically using local means analysis
(LMA) in the BrainVisa/Anatomist framework (http://
brainvisa.info, [42–44]). Automatic segmentation was preferred to
manually drawn regions of interest (ROIs), which can introduce a
user-dependent bias. In short, the LMA algorithm first extracts the
whole body of the rodent from the background before identifying
voxels in the core of organs based on the notion that their variation
in PET signal should be lower than those voxels at the organ
borders, which are more subject to variations driven by physiolog-
ical movement and spillover from neighbouring organs/vessels.
Neighbouring voxels are then identified based on the similarity of
their kinetics to these organ ‘cores.’ Ultimately, the implementation
in BrainVisa segments the whole body image into 200 regions
based on the similarity of kinetics of the voxels contained within
them. Within the brain (delineated using the CT images),
segmented ROIs were then manually selected and labelled under
the following scheme: (1) core of the LPS lesion (covering the right
Fig. 3. Average TACs for cerebellum (black) and contralateral (grey) reference regions for (R)-[11C]PK11195, [18F]GE-180 and
[18F]DPA-714 in LPS animals. At 40–60 min, the cerebellar uptake (%ID/cm3) was significantly higher for all three tracers
(p = 0.001) than the contralateral uptake
Fig. 4. Co-registered (sum 40–60 min) PET/CT images of representative animals dual-scanned with a and c (R)-[11C]PK11195
followed by either b [18F]GE-180 (top) or d [18F]DPA-714 (bottom). Inset top: example of regions defined by automatic
segmentation. Inset bottom: [18F]DPA-714 autoradiographic image showing increased specific uptake in the right striatum
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striatum and/or the region with the highest uptake), (2) edge 1 (ROI
around the core with the second highest uptake of tracer), (3) edge
2 (ROI with the third highest uptake), (4) a contralateral region
(ROI with the lowest uptake, used as a reference region in kinetic
analysis), (5) cerebellum and (6) skull edges (voxels on the edges
of the skull taken to be noise and/or spillover from regions outside
the brain, not included in the data analysis) (see top-right corner
inset Fig. 4). Where applicable, a region of fourth highest uptake
(edge 3) was also included in ROI segmentation. In the control
animals, regions of high and low brain uptakes, as well as
cerebellum and skull edges, were defined. ROIs’ volumes were
similar for all tracers (core 86 ± 20 mm3, edge 1 202 ± 3 mm3, edge
2 498 ± 114 mm3, edge 3 268 ± 31 mm3 and contralateral
217 ± 16 mm3, with a maximum variation in ROIs’ volumes across
tracers of 23 %).
The previous work published by our group has presented results
with partial volume correction (PVC). Although in our previous
study with high amplitude response in TSPO expression, group
differences were not affected by PVC being applied or not [23], for
low level NI models PVC might actually reduce the signal to
background ratio and therefore damp the PET signal. This is due to
PVC inherently amplifying noisy, high-frequency signals to reduce
spill-over effects. Therefore, in our model of low/mild NI, applying
PVC might be somewhat counter-productive. Having analysed
results with and without PVC, here we selected to present raw
(uncorrected) data, which showed consistent group differences
between tracers.
Data-Driven Method for the Extraction
of Reference Tissue Kinetics
The method by Yaqub et al. [36] is a successor to that by
Turkheimer et al. [45], using a pre-defined brain mask to segment
all masked voxel PET time activity curves (TACs) into four classes
(grey matter with specific binding, grey matter without specific
binding, white matter and blood). Subsequently, in dynamic PET
data, the reference tissue is selected as the tissue class with the
kinetic most similar to that of grey matter without specific binding.
This method requires segmented MR data for the generation of a
(camera-specific) population database. Since the spatial resolution
of the Inveon® small animal PET-CT camera is between 1 and
2 mm, it is not possible to resolve distinct grey and white matter
kinetics in the rat brain. Therefore, we replaced the MR-guided
tissue segmentation [36, 45] with an automated kinetic data
segmentation approach developed for preclinical PET data (LMA)
[42–44]. The LMA method, implemented in BrainVisa, produced
three classes of sufficient size (over 10 % of total brain voxels) in
the rat brain and with voxels which were located in spatial
proximity to each other. We additionally attempted to define more
classes (as used in clinical supervised clustering [36, 45]); however,
no more than three kinetically distinct classes were visible in the
stroke rodent brain (identifiable by TAC shape), suggesting that
this was the optimum number for class definition. This was
consistent for (R)-[11C]PK11195, [18F]GE-180 and [18F]DPA-714.
In our implementation, a population of adult male Wistar rats in
a model of focal cerebral ischaemia were used for class definition.
Six animals underwent transient right middle cerebral artery
occlusion (MCAO) for 60 min (data published previously and re-
analysed [23]) and were dual scanned with (R)-[11C]PK11195 and
[18F]GE-180 5 or 6 days later. In addition, four animals with
MCAO were scanned with (R)-[11C]PK11195 and [18F]DPA-714
(data re-analysed from [17]). All data were reconstructed and pre-
processed as described above. Brain masks [36] were extracted
from the individual CT images for each animal. The classes were
defined within the brain as ‘activated tissue’ represented by the core
of the infarct; ‘normal tissue’ from the contralateral ROI; and
‘tissue with intermediate binding’, represented by cerebral tissue
located between the core and contralateral tissue and in the
cerebellum. As described above, these regions were defined using
the BrainVISA LMA segmentation, for each animal, and TACs
were normalised (by subtracting from each frame its mean and
dividing it by its standard deviation, SD, to create a unit input) and
averaged to produce a population database. The algorithm was then
implemented on the dynamic images using the Matlab code,
SuperPK Software (Imperial Innovations, Imperial College Lon-
don, UK [45, 46], developed for clinical studies and adapted here
for preclinical class definitions), from the LPS animals to produce
cluster maps for normal, intermediate and activated tissue, as well
as a reference kinetic, based on the class of voxel most kinetically
similar to normal tissue identified in the training data set, for input
to the SRTM.
PET Data Modelling
Kinetic analysis of data was performed using the SRTM [47] in the
PMOD software package (version 3.6, PMOD Technologies Ltd.)
for ROIs (1) to (5). The model assumes a 1-tissue compartment
arrangement in the target region (lesion) and the reference region.
Input functions were derived using the contralateral hemisphere
ROI (region 4), cerebellum (region 5) and the supervised clustering
approach. R1 (ratio of tracer delivery in the target ROI vs. that in all
respective reference regions) and BPND were calculated for all
ROIs.
Immunohistochemistry
Brain sections, including the striatum, from five LPS animals which
were also scanned in vivo were stained for CD11b and glial
fibrillary acidic protein (GFAP) to confirm the presence of
microglia and astrocytes respectively. Staining for neuronal nuclei
was also completed using an anti-NeuN antibody. Sections from
four animals were also stained to investigate BBB integrity:
visualising tight junctions with claudin-5 and large protein
diffusion with IgG.
For all procedures described below, phosphate buffered saline
(PBS) at 100 mM was used. Rat brain sections were snap frozen in
isopentane and stored at −80 °C. Sections were then post-fixed in
paraformaldehyde (4 % in PBS) for 10 min and washed (3 × 5 min)
in PBS. Sections were incubated in 1 mg/ml sodium borohydride in
PBS (3 × 5 min) to reduce auto-fluorescence and washed again in
PBS (3 × 5 min). They were then permeabilised with 2 h of
incubation in 0.1 % Triton X-100 containing 3 % normal donkey
serum in PBS to block non-specific binding. Without further
washing, sections were incubated overnight at 4 °C with primary
antibodies in 3 % normal donkey serum/0.1 % Triton X-100 in
PBS. Double immunohistochemical staining was performed against
GFAP with rabbit anti-cow GFAP (Dako, 1:400) and CD11b
(OX42) with mouse anti-rat CD11b (Serotec, 1:1000). Adjacent
sections from the same animals were stained with mouse anti-
mouse NeuN (Chemicon, 1:1000). Sections were then washed
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(3 × 10 min) in PBS/Triton and incubated for 2 h at room
temperature with secondary antibodies (AlexaFluor® 488 nm
donkey anti-rabbit for GFAP, AlexaFluor® 594 nm donkey anti-
mouse for CD11b, or AlexaFluor® 594 nm donkey anti-mouse for
NeuN (Molecular Probes, Invitrogen)), all 1:500 in 3 % normal
donkey serum/0.1 % Triton X-100 in PBS and then washed again
(3 × 10 min) in PBS.
Following the same protocol, brain sections from two animals
injected with LPS from the in vivo study and two animals injected
with AMPA (positive control) were incubated with monoclonal
rabbit anti-claudin-5 (Sigma-Aldrich, 1:100) primary antibody and
AlexaFluor® 488 nm donkey anti-rabbit. To stain for endogenous
rat IgG infiltration in the brain parenchyma, adjacent sections were
incubated with AlexaFluor® 594 nm donkey anti-rat. AMPA-
injected animals were of the same strain and comparative age/
weight to LPS animals. Supplementary Table 2 provides a
summary of primary and secondary antibodies used during
immunohistochemistry.
All sections were mounted with a Prolong® Gold Antifade kit
(Molecular Probes, Invitrogen). Images were collected on an
Olympus BX51 upright microscope using 4×/0.13, 10×/0.30 or
40×/0.50 UPlanFLN objectives and captured using a Q-Capture
Retiga 6000 camera through Q-Capture Pro Software (Molecular
Devices). Specific band pass filter sets were used to prevent bleed
through from one channel to the next. Images were processed and
analysed using ImageJ (http://rsb.info.nih.gov/ij).
Autoradiography
In order to confirm the presence of specific TSPO binding,
[18F]DPA-714 autoradiography was performed with 20-μm brain
sections from five LPS animals (adjacent to those used for
immunohistochemistry). Sections were first incubated for 5 min in
cold Tris buffer (Trizma crystals (Sigma, UK), 50 mM adjusted to
pH 7.4 at 4 °C with 120 mM NaCl) and then incubated for 1 h at
room temperature with either [18F]DPA-714 (total binding) (98.7
GBq/μmol; 5 nM) or [18F]DPA-714 with excess PK11195 (5 μM)
to assess non-specific binding. Sections were rinsed twice for 2 min
with cold buffer and then once quickly with cold distilled water,
before being dried and exposed overnight to a Phosphor-Imager
screen (Fujifilm BAS-1800II, Raytek Scientific Ltd., Sheffield,
UK). Autoradiographs were visualised and analysed using AIDA
software (Raytest GmbH, Germany). ROIs were drawn manually
on the lesion and the contralateral area, and binding is expressed as
the intensity of photostimulated luminescence (PSL) per pixel.
Statistical Analysis
All data are expressed as mean ± SD. Paired Wilcoxon signed rank
tests were used to compare (R)-[11C]PK11195 and the correspond-
ing F-18 tracer uptake or BPND values obtained in the same animal
(dual tracer scans). Non-paired (R)-[11C]PK11195, [18F]GE-180
and [18F]DPA-714 results were compared using the Mann-Whitney
U test. Non-paired comparisons of tracers were performed as (R)-
[11C]PK11195[
18




F]DPA-714 (group 2) vs. [
18F]GE-180only
(group 3) (see Supplementary Table 1). Comparisons between all
animals scanned with [18F]GE-180 and [18F]DPA-714 (n = 11 vs.
n = 11) were also performed. Statistics were performed in
GraphPad Prism for Windows (v6.04, GraphPad Software, Inc.,
San Diego, CA, USA).
Results
PET Imaging
All PET images in LPS animals (groups 1–4) showed
localised increase in tracer uptake (%ID/cm3) in the core
ROI (Figs. 2 and 4, Table 1). Furthermore, the uptake in
edges 1, 2 and 3 was lower compared to the core and not
statistically different than the contralateral side, indicating a
gradual decrease in neuroinflammation with distance from
the injection site.
Non-Paired Scans
For non-paired scans, there was no significant difference in
40–60 min core or contralateral uptakes between tracers.
There were no significant differences between the core/
contralateral uptake ratios at 40–60 min between (R)-
[11C]PK11195 and either F-18 tracer when considering
non-paired groups of animals: (R)-[11C]PK11195[
18
F]DPA-
714 (2.26 ± 0.41, n = 6) vs. [
18F]GE-180only (2.76 ± 0.48,
n = 5) or (R)-[11C]PK11195[
18
F]GE-180 (2.43 ± 0.39, n = 6)
vs. [18F]DPA-714only (2.92 ± 0.43, n = 5). The unpaired
comparison of animals scanned with [18F]GE-180 (n = 11)
and animals scanned with [18F]DPA-714 (n = 11) showed no
significant difference in core/contralateral uptake at 40–
60 min (p = 0.47) or the core/contralateral ratio (Table 1).
Additionally, there were no significant differences between
animals scanned with [18F]GE-180only (n = 5) and [
18F]GE-
180 (n = 6), nor with [18F]DPA-714only (n = 5) and
[18F]DPA-714 (n = 6) (Table 1). There was also no
significant difference between the contralateral ROI and the
edges 1, 2, 3 and cerebellum ROIs (Table 1).
For comparison with the control (naïve) animals, all the
LPS-injected animals were pooled for each tracer. Average
contralateral uptakes in all LPS animals at 40–60 min






F]DPA-714, n = 12), [
18F]GE-180
(+[18F]GE-180on ly , n = 11) and [
18F]DPA-714
(+[18F]DPA-714only, n = 11) respectively) were not signif-
icantly different from the low uptake regions in control
animals (0.09 ± 0.01 % (n = 4), 0.08 ± 0.01 % (n = 5) and
0.05 ± 0.01 % (n = 4) for (R)-[11C]PK11195, [18F]GE-180
and [18F]DPA-714 respectively), supporting the use of the
contralateral ROI as reference region.
Dual Scans
For dual scans, there was no significant difference between
all the ROIs studied for all tracers. However, core/
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contralateral ratios were significantly higher (+40 ± 36 %)
for [18F]GE-180 than (R)-[11C]PK11195 (3.41 ± 1.09 vs.
2.43 ± 0.39, p = 0.03), while [18F]DPA-714 values were not
(2.80 ± 0.69 vs. 2.26 ± 0.41, p = 0.09, +25 ± 25 %; Table 1
and Fig. 2).
Kinetic Analysis
Previous work [17, 23] has shown that only paired scans can
truly account for inter-individual variability; thus, for the
kinetic analysis, only dual scan data were considered.
SRTM with Contralateral Reference Input
Table 2 shows BPND results for dual-scanned animals.
Average values calculated with a contralateral reference
input for animals scanned with (R)-[11C]PK11195 then
[18F]GE-180 were 1.25 ± 0.29 and 1.94 ± 0.75 respectively
(+57 ± 57 %, p = 0.03), while (R)-[11C]PK11195 vs.
[18F]DPA-714 dual scan BPND values were 1.11 ± 0.31 and
1.58 ± 0.54, respectively (+43 ± 34 %, p = 0.06).
SRTM with Cerebellar Reference Input
Overall, using a cerebellar reference input returned lower
BPND values than using a contralateral reference input
(p = 0.001 for all tracers) and BPND results were not
significantly different between tracers (0.60 ± 0.26 vs.
0.84 ± 0.46 for (R)-[11C]PK11195 vs. [18F]GE-180;
0.46 ± 0.17 vs. 0.43 ± 0.26 for (R)-[11C]PK11195 vs.
[18F]DPA-714, Table 2).
SRTM with Data-Driven Clustering Reference
Input
BPND values with a data-driven reference input function
were overall lower than those from a contralateral reference
region (p = 0.001 for (R)-[11C]PK11195 and [18F]DPA-714,
and p = 0.002 for [18F]GE-180), but were highly correlated
(Spearman’s correlation coefficient ρ = 0.83 and 0.90
respectively for dual scans). For dual-scanned animals, (R)-
[11C]PK11195 and [18F]GE-180 values were 0.83 ± 0.22
and 0.63 ± 0.43 respectively (p = 0.31, n.s.), while (R)-
[11C]PK11195 and [18F]DPA-714 BPND values were
0.75 ± 0.20 and 0.49 ± 0.20 respectively (p = 0.03, Table 2).
Autoradiography
Autoradiographs confirmed the presence of specific
[18F]DPA-714 binding in the ipsilateral striatum compared
to the contralateral striatum. Quantification of the autoradi-
ography revealed a 5.62 ± 0.72-fold increase in specific
binding in the ipsilateral striatum when compared to the
contralateral striatum (Fig. 4 (insert bottom right) and
Supplementary Fig. 3).
Immunohistochemistry
Anti-rat IgG immunohistochemistry will label rat IgG in
blood vessels; as a large protein, IgG should not diffuse into
the brain if the BBB is intact. Our staining indicated that rat
IgG were still localised in blood vessels in the LPS model,
hence supporting presence of an intact BBB, whereas in the
AMPA model the staining of blood vessels was lost and was
diffuse in the brain parenchyma, indicating BBB leakage.
This was confirmed by immunohistochemistry of the tight-
Table 1. Regional uptakes expressed in %ID/cm3 and core/contralateral ratio for each group (40–60 min sum image). Data expressed as mean ± SD
Group Tracer Core Contralateral Core/contralateral
ratio
Cerebellum Edge 1 Edge 2 Edge 3
1 (R)-[11C]PK11195([
18
F]GE-180) 0.19 ± 0.03 0.08 ± 0.02 2.43 ± 0.39 0.12 ± 0.02 0.14 ± 0.03 0.11 ± 0.02 0.08 ± 0.02
[18F]GE-180 0.24 ± 0.08 0.08 ± 0.03 3.41 ± 1.09* 0.13 ± 0.04 0.16 ± 0.04 0.11 ± 0.03 0.08 ± 0.03
2 (R)-[11C]PK11195([
18
F]DPA-714) 0.20 ± 0.05 0.09 ± 0.03 2.26 ± 0.41 0.14 ± 0.04 0.16 ± 0.05 0.13 ± 0.05 0.11 ± 0.04
[18F]DPA-714 0.19 ± 0.03 0.07 ± 0.03 2.80 ± 0.69 0.14 ± 0.03 0.14 ± 0.03 0.12 ± 0.05 0.09 ± 0.05
3 [18F]GE-180only 0.19 ± 0.08 0.07 ± 0.02 2.76 ± 0.48 0.15 ± 0.04 0.15 ± 0.05 0.10 ± 0.03 0.09 ± 0.03
4 [18F]DPA-714only 0.18 ± 0.04 0.06 ± 0.01 2.92 ± 0.43 0.12 ± 0.02 0.13 ± 0.03 0.09 ± 0.02 0.09 ± 0.06
Asterisk indicates BPND values significantly different from (R)-[
11C]PK11195 (paired Wilcoxon signed rank test, p G 0.05)








Contralateral 1.25 ± 0.29 1.94 ± 0.75* 1.11 ± 0.31 1.58 ± 0.54
Cerebellum 0.60 ± 0.26 0.84 ± 0.46 0.46 ± 0.17 0.43 ± 0.26
Supervised clustering 0.83 ± 0.22 0.64 ± 0.42 0.75 ± 0.20 0.49 ± 0.20*
Asterisk indicates BPND values significantly different from (R)-[
11C]PK11195 (paired Wilcoxon signed rank test, p G 0.05)
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junction protein claudin-5, as LPS animals showed similar
intact vessels in the ipsilateral and contralateral area, while
in AMPA-challenged animals, the vessels were clearly
damaged (Fig. 5a) in the ipsilateral side, indicating a
compromised BBB.
Activated microglial cells (CD11b) were observed in
large numbers in the core of the inflamed area compared to
the contralateral hemisphere, as were astrocytes (GFAP)
(Fig. 5b). NeuN stained nuclei showed no obvious difference
between contralateral and ipsilateral striatum, supporting that
there was no neuronal loss induced by the LPS injection
(Fig. 5c).
Discussion
PET Imaging and Ex Vivo Observations
Although results from rodents are not directly transferable to
humans due to inter-species differences, preclinical studies
are still valuable for assessment and characterisation of
tracer behaviour, especially where models can be developed
to mimic clinically relevant levels of inflammation. The
primary aim of this study was to quantitatively compare the
recently developed second-generation TSPO radioligand
[18F]GE-180 with the more well-established [18F]DPA-714
and the original (R)-[11C]PK11195 in a rat model of low/
mild focal inflammation. Recently published work has
shown that both F-18 labelled tracers have an improved
SNR over (R)-[11C]PK11195 in models of acute inflamma-
tion [17, 22, 23, 28], but to date, there is neither reported
investigation comparing these new tracers nor looking at
their performance in a model producing a lower level
inflammation (∼2-fold increase in TSPO PET signal), which
is more similar to the levels observed in neurodegenerative
diseases than stroke [17, 23], excitotoxic lesions [16, 48] or
high doses of LPS [28, 34] (∼4–6-fold increase in TSPO
PET signal). The second aim of this study was to assess the
kinetic quantitation methodology via use of the SRTM with
different reference input functions. Non-terminal preclinical
kinetic modelling has so far been limited to semi-
quantitation (SUV) or use of an anatomical reference region
in unilateral models. In order to evaluate methods that could
be used in neurodegenerative diseases, such as AD trans-
genic models, which display low levels of neuroinflamma-
tion and where a contralateral reference tissue does not exist,
we have compared here the BPND values obtained with the
SRTM and three different reference input functions: (1) a
contralateral region, (2) a cerebellar region, (3) a reference
Fig. 5. a Claudin-5 (×60 magnification) and IgG (×20 magnification) staining in ipsilateral and contralateral striatum for LPS and
positive control AMPA-challenged animals. Claudin-5 staining revealed no differences between contralateral and ipsilateral
sides in the LPS-challenged animals, while for AMPA-challenged animals, there was visible damage to vessels in the ipsilateral
side and some disruption in the contralateral hemisphere. IgG appears normal in ipsilateral and contralateral sides of LPS
animals but shows signs of leakage in the ipsilateral side of AMPA animals. b Staining for microglia (CD11b, red) and astrocytes
(GFAP, green), merged at ×10 and ×20 (white rectangles) magnification; c NeuN staining at ×20 magnification in core and
contralateral striatum
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kinetic derived from a data-driven supervised clustering
approach.
Previous preclinical studies using an LPS model have
typically used larger doses of the endotoxin, inducing high-
level inflammation [22, 28]. Moreover, previous publica-
tions did not compare (R)-[11C]PK11195 with second-
generation TSPO tracers [28, 34] in the more challenging
setting of low/mild neuroinflammation and animals were not
dual scanned with the tracers [22]. Finally, the comparison
between (R)-[11C]PK11195 and [18F]GE-180 performed by
Dickens et al. only used the contralateral reference region as
input for modelling.
Our study showed that [18F]GE-180 uptake and BPND
were significantly higher than those of (R)-[11C]PK11195,
while [18F]DPA-714 were not. Figure 2e–f shows the
core/contralateral uptake ratios for dual-scanned animals;
it is inferable from Fig. 2e that the significant difference
seen between [18F]GE-180 and (R)-[11C]PK11195 may be
driven by three particular animals of the six scanned with
both (R)-[11C]PK11195 and [18F]GE-180. These animals
are also likely to drive the increased variability observed
with [18F]GE-180 over the other tracers. We also
performed a comparison in ‘non-paired’ animals individ-
u a l l y s c a n n e d w i t h d i f f e r e n t t r a c e r s ( (R ) -
[11C]PK11195[
18





18F]DPA-714, Table 1). In-
terestingly, core/contralateral uptake ratios between 40
and 60 min post-injection for unpaired groups were not
significantly higher for either [18F]GE-180 or [18F]DPA-
714 when compared to (R)-[11C]PK11195, or compared to
one another. Altogether, the lack of differences between
[18F]DPA-714 and [18F]GE-180 suggests that both tracers
provide similar readouts of neuroinflammation.
These observations also highlight (1) that the differences
in sensitivity (if any) between the three tracers used in this
study are rather small (2) that, as hypothesised, the inherent
variability within an experiment or populations makes
quantification more challenging when measuring low/mild
level of neuroinflammation and (3) further supports the
importance of dual scanning in the same subject to truly
compare the performance of tracers both in preclinical and
clinical settings.
Ex vivo experiments were performed in order to confirm
the in vivo observations. Firstly, immunohistochemistry
was performed with CD11b to assess microglial presence
in the core of the LPS injection site, GFAP staining for
astrocytic activation, NeuN to evaluate neuronal loss and
claudin-5 and IgG to assess BBB disruption. Results
supported the PET findings; both activated microglia and
astrocytes were significantly present in the right striatum
compared to the left (contralateral) side. Autoradiography
also confirmed the presence of TSPO specific binding in
the ipsilateral striatum while the NeuN staining showed
no neuronal loss in the right striatum. Finally, claudin-5
staining showed no BBB disruption compared to a
positive control AMPA model (Fig. 5a).
Although this study was designed to directly compare the
three tracers in vivo, comparison of [18F]GE-180 vs.
[18F]DPA-714 in the same animal was not practically
feasible due to the rapid progression of TSPO expression
over 24 h as induced by LPS injection, requiring the scans to
be conducted within hours, and the constraints imposed by
the half-life of F-18 and the tracer production. Similarly,
considering the difference in tracer pharmacokinetics, the
comparison of these two tracers by in vitro autoradiography
would not have yielded relevant information regarding their
in vivo behaviour as PET tracers, hence our comparison of
unpaired scans for these two tracers.
PET Data Modelling
In the case of a pathologically damaged BBB, the tracer
gains access to the brain parenchyma; thus the extent of
binding to TSPO is affected non-trivially and should be
accounted for in kinetic modelling. Here, ex vivo investiga-
tion of the BBB disruption in LPS-challenged animals vs.
positive control AMPA-challenged animals showed no
significant BBB disruption in the inflamed area with this
low dose of LPS when compared to the AMPA-treated
animals (Fig. 5a). Additionally, R1 values calculated using
the contralateral reference region were close to unity in the
core of the inflamed area for all animals, suggesting that
tracer diffusion to the contralateral (reference) and ipsilateral
regions was similar. This is not the case in strong excitotoxic
or stroke models, which can affect quantification [23].
When using the contralateral ROI, only the BPND[
18
F]GE-
180 was significantly higher than BPND-(R)-[
11
C]PK11195, and
as for core/contralateral ratio, BPND[
18
F]DPA-714 showed a
non-significant trend to increase (Table 2). When compared
to the contralateral region, both a cerebellar input and a
supervised clustering derived input produced significantly
lower BPND values for all tracers. Using a cerebellar input
showed no group differences between (R)-[11C]PK11195
and second-generation tracers in paired comparisons, while a
cluster-derived input identified significantly lower BPND
values with [18F]DPA-714 in animals dual-scanned with
(R)-[11C]PK11195. The blood perfusion of the cerebellum in
rodents is different than that in the brain and leads to a
different tracer pharmacokinetic (i.e., a higher peak and
uptake than in the normal brain/contralateral ROI, Fig. 3). It
is also possible that the cerebellum contains some specific
TSPO binding. Together, these two factors would lower the
BPND values calculated in the core of the inflamed area by
over-estimating the input of the reference tissue.
By the same rationale, a cluster-derived reference region
could contain some specific binding, therefore introducing a
bias; the MCAO model may not be optimal to define a
reference cluster, as the ‘healthy’ tissue could itself contain a
compartment of specifically bound tracer, further complicat-
ing the derivation of TSPO-free reference voxels in the LPS
animal brains. However, this is unlikely since, in a
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comparison of the region of lowest uptake in control animals
to the contralateral reference region in LPS animals, no
significant difference in uptake was observed, supporting the
use of the contralateral ROI as healthy reference tissue in
this model. We applied this approach by reducing and
reassigning the number of partitionable classes compared to
the clinically established method, producing significantly
lower BPND values for all tracers than a contralateral
reference input to the SRTM. Clinical studies have used
four or six class-supervised clustering; having also attempted
to define four classes in the rodent brain (data not shown),
we saw no obvious improvement to the BPND results from
the LPS animals. This could be due to a number of factors:
(i) unlike in the stroke model, the lower level of neuroin-
flammation induced in this LPS model may inherently not
be separable into three or more kinetically distinct classes
and/or (ii) the supervised clustering algorithm as it stands is
not fit to use with preclinical images which have lower
number of voxels to be used to identify classes.
Furthermore, [18F]DPA-714 BPND values were signifi-
cantly lower than those from (R)-[11C]PK11195, while
[18F]GE-180 results were not (Table 2). We speculate that
this difference could be the result of voxels exhibiting
pathology-related signal in LPS animals being mistakenly
classed as normal tissue by the supervised clustering
algorithm. In defining classes in the training data set, we
were unable to identify a blood pool class such as that used
in clinical supervised clustering [45], as the venous sinus in
the rodent brain is smaller in diameter than the resolution of
the PET camera, and external derivation (from, for example,
the left ventricle of the heart) was not possible due to field of
view limitations. The intermediate binding class defined
instead, while reliably identified by the LMA brain
segmentation, was kinetically not orthogonal to the normal
tissue class. As these three radiotracers have similar
affinities for TSPO, it is more likely that the supervised
clustering algorithm mis-identified some ‘intermediate’
binding voxels as normal tissue leading to lower and slightly
more variable BPND values for all tracers and hence the
absence of significant differences between BPND for
[18F]GE-180 and (R)-[11C]PK11195. Finally, if [18F]DPA-
714 is more sensitive to these effects (i.e., if the voxels
classed as normal tissue are more contaminated by TSPO-
related signal, e.g., through inherently increased levels of
microglial activation in these animals), it may explain the
significant difference seen when estimating BPND with the
supervised clustering approach.
Overall, these results suggest that (1) further work on the
development and implementation of this method for preclin-
ical imaging should be performed, and (2) the automatic
segmentation of ROIs as implemented in the BrainVisa
platform or PMOD® is currently the best approach, although
unfortunately best suited for models with clearly identifiable
rather than diffuse areas of neuroinflammation.
A recent study by Ory and colleagues using [18F]DPA-
714 [34] validated the use of a reference tissue model with
the contralateral striatum as input, producing BPND values
which correlated well with a two-tissue compartment
modelling approach. Interestingly, using a cerebellar input
function to the SRTM in their high-dose LPS model
produced BPND results which were also highly correlated
with blood modelling, albeit with higher bias and producing
BPND values lower than any other reference region, similar
to what we observed in the present study. Discrepancies in
these results, as well as those using the data-driven
supervised clustering approach, which was unable to identify
a suitable class of reference voxels, are most likely related to
differences in the inflammatory responses induced by high
(50 μg) and low dose (1 μg) of LPS. However, high doses of
LPS inducing a neuroinflammatory response similar to what
is observed after acute neurodegeneration are not represen-
t a t ive o f pa tho log ica l cond i t i ons wi th lower
neuroinflammatory levels, such as neurodegenerative dis-
eases. Interestingly, the study also used a 90-min imaging
window with this high-dose LPS injection; in the current
study, we were able to show differences between tracers by
the 60 min time point, suggesting that it is not necessary to
scan for longer time periods with a low-dose LPS model or
in a stroke model [17, 23]. Furthermore, it is well described
in the TSPO imaging literature [49–51] that models or
clinical cases in which a strong neuroinflammation (such as
in stroke) are much easier to model consistently, whereas in
the case of low or subtle neuroinflammation levels as
observed in neurodegenerative diseases, the modelling is
far more challenging, leading to discrepancies between
studies. Considering the failure of the data-driven supervised
clustering approach presented here, it is clear that further
work is needed to determine a reliable reference tissue
allowing the accurate quantification of TSPO tracer in
preclinical studies without the need of performing arterial
blood sampling when models of neurodegeneration such as
transgenic mice or rats are used.
Conclusions
The second-generation TSPO-PET radiotracer [18F]GE-180
showed an increased signal to noise ratio over (R)-
[11C]PK11195 when considering dual scans whereas
[18F]DPA-714 did not. However, the comparison of un-
paired scans did not reveal such differences. The discrep-
ancy between the statistical group results from paired and
non-paired comparisons highlights the importance of
performing dual scans for direct tracer comparison. More-
over, no significant differences were found between
[18F]DPA-714 and [18F]GE-180. Altogether, these results
suggest that when measuring low level of neuroinflamma-
tion, the differences between second-generation tracers
(between them or when compared to (R)-[11C]PK11195)
are small in term of sensitivity, while retaining their
attractiveness in term of of-site use due to the longer F-18
half-life. Cerebellar and data-driven inputs to the SRTM
were unable to produce comparable BPND values to those
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using a contralateral reference region. The choice of the
contralateral ROI as reference tissue was supported by the
fact that comparison between tracer uptakes in the contra-
lateral ROI and healthy animals showed no significant
difference and that ex vivo staining showed that the
contralateral ROI contained very few activated microglia.
Our study however also highlighted the remaining issue that
when a low level of neuroinflammation present and no
anatomically defined reference region can be identified,
there is still no well-established method to identify a
reference tissue in preclinical studies.
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